Chemotherapy-induced neuropathy

Journal of the Peripheral Nervous System

Volumn 13, Issue 1, 2008, Pages 27-46

  Windebank, Anthony J ^a   Grisold, Wolfgang ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Chemotherapy agents; Neurotoxicity; Neurotoxins; Peripheral nervous system; Prevention

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CORTICOTROPIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; GABAPENTIN; GLUTATHIONE; IFOSFAMIDE; NAVELBINE; NITROSOUREA; OXALIPLATIN; PACLITAXEL; PREGABALIN; PROCARBAZINE; RECOMBINANT ERYTHROPOIETIN; SURAMIN; TAXANE DERIVATIVE; THALIDOMIDE; THIOTEPA; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ADRENERGIC SYSTEM; ANEMIA; BLADDER CANCER; BLOOD TRANSFUSION; BRAIN DISEASE; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHOLINERGIC SYSTEM; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DEMYELINATING NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSESTHESIA; ELECTROPHYSIOLOGY; ESOPHAGUS CANCER; GASTROINTESTINAL MOTILITY DISORDER; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HEART FIBRILLATION; HEART PALPITATION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMPOTENCE; IRRITABILITY; LABORATORY TEST; LIMB WEAKNESS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM TUMOR; MEDULLOBLASTOMA; MENINGIOMA; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OCCUPATIONAL THERAPY; ORTHOSTATIC HYPOTENSION; OVARY CANCER; PAIN; PARANEOPLASTIC NEUROPATHY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REFLEX DISORDER; REHABILITATION CARE; REVIEW; RISK FACTOR; SARCOMA; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; SPINAL CORD DISEASE; TESTIS CANCER; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; WEAKNESS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; PLATINUM COMPOUNDS;

EID: 40849086432     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2008.00156.x     Document Type: Review

References (189)

1. Albers J, Chaudhry V, Cavaletti G, Donehower R (2007). Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev CD005228.
2. Allegra CJ, Grem JL (1997). Antimetabolites. In : Cancer Principles and Practice in Oncology, 5th Edn. De Vita V, Hellman S, Rosenberg SA (Eds). Lippincott-Raven, Philadelphia. pp 432 452.
3. Anzil AP, Blinzinger K, Herrlinger H (1976). Fenestrated blood capillaries in rat cranio-spinal sensory ganglia. Cell Tissue Res 167 : 563 567.
4. Apfel S (2000). Taxoids. In : Experimental and Clinical Neurotoxicology, 2nd Edn. Schaumburg H, Spencer P (Eds). Oxford University Press, New York. pp 1135 1139.
5. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, Iconomou G, Kalofonos HP (2005). Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64 : 26 31.
6. Bakshi N, Maselli RA, Gospe SM Jr., Ellis WG, McDonald C, Mandler RN (1997). Fulminant demyelinating neuropathy mimicking cerebral death. Muscle Nerve 20 : 1595 1597.
7. Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS (2006). A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol 83 : 309 313.
8. Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L (2005). Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41 : 1746 1750.
9. Bianchi R, Brines M, Lauria G, Savino C, Gilardini A, Nicolini G, Rodriguez-Menendez V, Oggioni N, Canta A, Penza P, Lombardi R, Minoia C, Ronchi A, Cerami A, Ghezzi P, Cavaletti G (2006). Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 12 : 2607 2612.
10. Bigotte L, Olsson Y (1982). Retrograde transport of doxorubicin (adriamycin) in peripheral nerves of mice. Neurosci Lett 32 : 217 221.
11. Bleck TP, Jacobsen J (1991). Prolonged survival following the inadvertent intrathecal administration of vincristine: clinical and electrophysiologic analyses. Clin Neuropharmacol 14 : 457 462.
12. Bogliun G, Marzorati L, Marzola M, Miceli MD, Cantu MG, Cavaletti G (1996). Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynecol Cancer 6 : 415 419.
13. Boillot A, Cordier A, Guerault E, Julliot MC, Balvay P, Billerey C, Barale F (1989). A rare case of severe toxic peripheral neuropathy: poisoning by podophyllin. Apropos of 1 case. J Toxicol Clin Exp 9 : 409 412.
14. Boogerd W, Moffie D, Smets LA (1990). Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis. Cancer 65 : 452 457.
15. Brat DJ, Windebank AJ, Brimijoin S (1992). Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 261 : 803 810.
16. Briani C, Zara G, Rondinone R, Della Libera S, Ermani M, Ruggero S, Ghirardello A, Zampieri S, Doria A (2004). Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 62 : 2288 2290.
17. Burns BV, Shotton JC (1998). Vocal fold palsy following vinca alkaloid treatment. J Laryngol Otol 112 : 485 487.
18. Cairncross G, Swinnen L, Bayer R, Rosenfeld S, Salzman D, Paleologos N, Kaminer L, Forsyth P, Stewart D, Peterson K, Hu W, Macdonald D, Ramsay D, Smith A (2000). Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro-oncol 2 : 114 119.
19. Camps C, Felip E, Sanchez JM, Massuti B, Artal A, Paz-Ares L, Carrato A, Alberola V, Blasco A, Baselga J, Astier L, Voi M, Rosell R (2005). Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 16 : 597 601.
20. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G (1995). Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13 : 26 32.
21. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G (2002). Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20 : 3478 3483.
22. Cavaletti G, Nobile-Orazio E (2007). Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 92 : 1308 1310.
23. Cavaletti G, Bogliun G, Zincone A, Marzorati L, Melzi P, Frattola L, Marzola M, Bonazzi C, Cantù MG, Chiari S, Galli A, Bregni M, Gianni MA (1998a). Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res 18 : 3797 3802.
24. Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G (1998b). Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9 : 443 447.
25. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 61 : 1297 1300.
26. Cavaletti G, Beronio A, Reni L, Ghiglione E, Schenone A, Briani C, Zara G, Cocito D, Isoardo G, Ciaramitaro P, Plasmati R, Pastorelli F, Frigo M, Piatti M, Carpo M (2004). Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 62 : 2291 2293.
27. Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR (1996). A prospective study of suramin-induced peripheral neuropathy. Brain 119 (part 6 2039 2052.
28. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G (2002). Thalidomide-induced neuropathy. Neurology 59 : 1872 1875.
29. Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW (2003). Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60 : 337 340.
30. Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B (2003). Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 25 : 316 320.
31. Cheson BD, Vena DA, Foss FM, Sorensen JM (1994). Neurotoxicity of purine analogs: a review. J Clin Oncol 12 : 2216 2228.
32. Cho ES (1977). Toxic effects of adriamycin on the ganglia of the peripherial nervous system: a neuropathological study. J Neuropathol Exp Neurol 36 : 907 915.
33. Clark DW (1985). Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29 : 342 375.
34. Colomer R, Llombart-Cussac A, Lluch A, Barnadas A, Ojeda B, Caranana V, Fernandez Y, Garcia-Conde J, Alonso S, Montero S, Hornedo J, Guillem V (2004). Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 15 : 201 206.
35. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T (1999). Total neuropathy score: validation and reliability study. Neurology 53 : 1660 1664.
36. Curran MP, Plosker GL (2002). Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer. Drugs Aging 19 : 695 721.
37. Davis ID, Kiers L, MacGregor L, Quinn M, Arezzo J, Green M, Rosenthal M, Chia M, Michael M, Bartley P, Harrison L, Daly M (2005). A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11 : 1890 1898.
38. DeAngelis LM, Gnecco C, Taylor L, Warrell RP Jr. (1991). Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer 67 : 2241 2246.
39. Dormann AJ, Grunewald T, Wigginghaus B, Huchzermeyer H (1998). Gemcitabine-associated autonomic neuropathy. Lancet 351 : 644.
40. Dyck PJ, Hughes RAC, O'Brien PC (2005). Quantitating Overall Neuropathic Symptoms, Impairments, and Outcomes. In : Peripheral Neuropathy, 4th Edn. Dyck PJ, Thomas PK (Eds). Elsevier Saunders, Philadelphia, pp 1031 1051.
41. Dyke RW (1989). Treatment of inadvertent intrathecal injection of vincristine. N Engl J Med 321 : 1270 1271.
42. Eeles R, Tait DM, Peckham MJ (1986). Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer. Cancer Treat Rep 70 : 905 907.
43. Evans DA (1969). An improved and simplified method of detecting the acetylator phenotype. J Med Genet 6 : 405 407.
44. Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C (1996). Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol 39 : 150 156.
45. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA (1994). A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17 : 1281 1289.
46. Fu KK, Kai EFY, Leung CK (1995). Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. J Clin Pharm Ther 20 : 167 172.
47. Fullerton PM, O'Sullivan DJ (1968). Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry 31 : 543 551.
48. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002). Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29 : 21 33.
49. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR, Williams L, Diasio RB, Perez E, Karp DD, Reich SD, McCarroll K, Hoff JV 1995). Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 13 : 490 496.
50. Gedlicka C, Scheithauer W, Schull B, Kornek GV (2002). Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20 : 3359 3361.
51. Gedlicka C, Kornek GV, Schmid K, Scheithauer W (2003). Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 14 : 339 340.
52. Ghirardi O, Lo Giudice P, Pisano C, Vertechy M, Bellucci A, Vesci L, Cundari S, Miloso M, Rigamonti LM, Nicolini G, Zanna C, Carminati P (2005a). Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 25 : 2681 2687.
53. Ghirardi O, Vertechy M, Vesci L, Canta A, Nicolini G, Galbiati S, Ciogli C, Quattrini G, Pisano C, Cundari S, Rigamonti LM (2005b). Chemotherapy-induced allodinia: neuroprotective effect of acetyl-L-carnitine. In Vivo 19 : 631 637.
54. Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A (2003). Thalidomide-induced neuropathy: a ganglionopathy? Neurology 60 : 877 878.
55. Gill JS, Windebank AJ (1998a). Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101 : 2842 2850.
56. Gill JS, Windebank AJ (1998b). Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ 5 : 876 883.
57. Gill JS, Hobday KL, Windebank AJ (1995). Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures. Exp Neurol 133 : 113 124.
58. Gill JS, Connolly DC, McManus MJ, Maihle NJ, Windebank AJ (1996). Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons. J Neurochem 66 : 963 972.
59. Glantz MJ, Choy H, Kearns CM, Cole BF, Mills P, Zuhowski EG, Saris S, Rhodes CH, Stopa E, Egorin MJ (1996). Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14 : 600 609.
60. Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, Walters BC, Recht LD (1998). Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82 : 733 739.
61. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschluter M (2006). A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132 : 584 593.
62. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM (2003). Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 21 : 3761 3769.
63. Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD (1996). Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 77 : 1356 1362.
64. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY (2001). Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124 : 1138 1148.
65. Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M, Stewart DJ (1992). Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10 : 795 803.
66. Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR, Rapoport SI (1990). Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother Pharmacol 26 : 263 268.
67. Grisold W, Vass A, Schmidhammer R, Zifko U (2007). Rehabilitation of neuropathies. Crit Rev Phys Rehabil Med 19 : 19 53.
68. Grothey A (2003). Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30 : 5 13.
69. Grunberg SM, Sonka S, Stevenson LL, Muggia FM (1989). Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol 25 : 62 64.
70. Gutin PH, Levi JA, Wiernik PH, Walker MD (1977). Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 61 : 885 887.
71. Hamers FPT, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt JP, Gispen WH (1993). Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53 : 544 549.
72. Hamilton S (2005). Hand-foot syndrome. http://www.chemocare.com/managing/ handfoot_syndrome.asp
73. Hansen RA, Gartlehner G, Powell GE, Sandler RS (2007). Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 5 : 729 735.
74. Hansen SW (1990). Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. BMJ 300 : 511 512.
75. Hansen SW (1992). Late-effects after treatment for germ-cell cancer with cisplatin, vinblastine, and bleomycin. Dan Med Bull 39 : 391 399.
76. Harila-Saari AH, Huuskonen UE, Tolonen U, Vainionpaa LK, Lanning BM (2001). Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials. Med Pediatr Oncol 36 : 345 351.
77. Hildebrand J (2006). Neurological complications of cancer chemotherapy. Curr Opin Oncol 18 : 321 324.
78. Hildebrandt G, Holler E, Woenkhaus M, Quarch G, Reichle A, Schalke B, Andreesen R (2000). Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol 11 : 743 747.
79. Hilkens PH, Verweij J, Vecht CJ, Stoter G, van den Bent MJ (1997). Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 8 : 187 190.
80. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE (1976). Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res 36 : 3798 3802.
81. Hohneker JA (1994). A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 21 : 42 46 discussion 46-47.
82. Hovestadt A, van der Burg MEL, Verbiest HBC, van Putten WLJ, Vecht CJ (1992). The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol 239 : 143 146.
83. Hu J, Fang J, Dong Y, Chen SJ, Chen Z (2005). Arsenic in cancer therapy. Anticancer Drugs 16 : 119 127.
84. Hussein MA (2005). Lenalidomide: patient management strategies. Semin Hematol 42 : S22 S25.
85. Igarashi M, Thompson EI, Rivera GK (1995). Vincristine neuropathy in type I and type II Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy). Med Pediatr Oncol 25 : 113 116.
86. International Collaborative Ovarian NeoPlasm Group (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360 : 505 515.
87. Ionasescu VV (1995). Charcot-Marie-Tooth neuropathies: from clinical description to molecular genetics. Muscle Nerve 18 : 267 275.
88. Iqbal Z, Ochs S (1980). Uptake of Vinca alkaloids into mammalian nerve and its subcellular components. J Neurochem 34 : 59 68.
89. Jackson DV Jr., Castle MC, Poplack DG, Bender RA (1980). Pharmacokinetics of vincristine in the cerebrospinal fluid of subhuman primates. Cancer Res 40 : 722 724.
90. Jacobs JM (1978). Vascular permeability and neurotoxicity. Environ Health Perspect 26 : 107 116.
91. Johnson NT, Crawford SW, Sargur M (1987). Acute acquired demyelinating polyneuropathy with respiratory failure following high-dose systemic cytosine arabinoside and marrow transplantation. Bone Marrow Transplant 2 : 203 207.
92. Kalcioglu MT, Kuku I, Kaya E, Oncel S, Aydogdu I (2003). Bilateral hearing loss during vincristine therapy: a case report. J Chemother 15 : 290 292.
93. Kanat O, Evrensel T, baran I, Coskun H, Zarifoglu M, Turan OF, Kurt E, Demiray M, Gonullu G, Manavoglu O (1920). Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol 3 : 237 245.
94. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996). Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14 : 2101 2112.
95. Kiernan MC, Krishnan AV (2006). The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 13 : 2901 2907.
96. Koeppen S, Verstappen CC, Korte R, Scheulen ME, Strumberg D, Postma TJ, Heimans JJ, Huijgens PC, Kiburg B, Renzing-Kohler K, Diener HC (2004). Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 130 : 153 160.
97. Koh S, Nelson MD Jr., Kovanlikaya A, Chen LS (1999). Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 21 : 576 578.
98. Kornblau SM, Cortes-Franco J, Estey E (1993). Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia 7 : 378 383.
99. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, Krarup C (1993). Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain 116 : 1017 1041.
100. LaRocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, Dalakas MC (1990). Suramin-induced polyneuropathy. Neurology 40 : 954 960.
101. Lee JJ, Swain SM (2006). Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24 : 1633 1642.
102. Lee JJ, Low JA, Croarkin E, Parks R, Berman AW, Mannan N, Steinberg SM, Swain SM (2006). Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol 24 : 2084 2091.
103. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004). Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29 : 387 392.
104. Leonard GD, Wagner MR, Quinn MG, Grem JL (2004). Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy. Anticancer Drugs 15 : 733 735.
105. Leone R, Fracasso ME, Soresi E, Cimino G, Tedeschi M, Castoldi D, Monzani V, Colombi L, Usari T, Bernareggi A (1992). Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother Pharmacol 29 : 385 390.
106. Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau F, Scambia G (2003). Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14 : 1086 1093.
107. Low PA, Vernino S, Suarez G (2003). Autonomic dysfunction in peripheral nerve disease. Muscle Nerve 27 : 646 661.
108. Lugassy G, Shapira A (1990). Sensorineural hearing loss associated with vincristine treatment. Blut 61 : 320 321.
109. Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crino L (2005). A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 91 : 135 138.
110. Marshall J (1966). The Landry-Guillain-Barré syndrome. Brain 86 : 55 66.
111. Martin Algarra S, Henriquez I, Rebollo J, Artieda J (1990). Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases. Anticancer Drugs 1 : 33 35.
112. Matthews SJ, McCoy C (2003). Thalidomide: a review of approved and investigational uses. Clin Ther 25 : 342 395.
113. Mazumder A, Jagannath S (2006). Thalidomide and lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 19 : 769 780.
114. McDonald ES, Randon KR, Knight A, Windebank AJ (2005). Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 18 : 305 313.
115. McKeage MJ (1995). Comparative adverse effect profiles of platinum drugs. Drug Safety 13 : 228 244.
116. 1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem 268 : 27299 27306.
117. Mesa RA (2006). Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther 6 : 313 319.
118. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM (2006). Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24 : 4507 4514.
119. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA 1990). Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322 : 352 358.
120. Mollman JE, Hogan WM, Glover DJ, McCluskey LF (1988). Unusual presentation of cis-platinum neuropathy. Neurology 38 : 488 490.
121. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD (2001). Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 24 : 1050 1057.
122. Moore BE, Somers NP, Smith TW (2002). Methotrexate-related nonnecrotizing multifocal axonopathy detected by beta-amyloid precursor protein immunohistochemistry. Arch Pathol Lab Med 126 : 79 81.
123. Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, Waggoner SE (2003). Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21 : 4207 4213.
124. Moudgil SS, Riggs JE (2000). Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother 34 : 1136 1138.
125. Nagore E, Insa A, Sanmartin O (2000). Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 1 : 225 234.
126. Nicolaou KC, Yang Z, Liu JJ, Ueno H, Nantermet PG, Guy RK, Claiborne CF, Renaud J, Couladouros EA, Paulvannan K, Sorenson EJ (1994). Total synthesis of taxol. Nature 367 : 630 634.
127. O'Brien TJ, Cascino GD, So EL, Hanna DR (1998). Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology 51 : 1034 1039.
128. Olsson Y (1971). Studies on vascular permeability in peripheral nerves. IV. Distribution of intravenously injected protein tracers in the peripheral nervous system of various species. Acta Neuropathol (Berl) 17 : 114 126.
129. Openshaw H, Beamon K, Synold TW, Longmate J, Slatkin NE, Doroshow JH, Forman S, Margolin K, Morgan R, Shibata S, Somlo G (2004). Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 10 : 461 467.
130. Openshaw H, Slatkin NE, Stein AS, Hinton DR, Forman SJ (1996). Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 78 : 1899 1905.
131. Orejana-Garcia AM, Pascual-Huerta J, Perez-Melero A (2003). Charcot-Marie-Tooth disease and vincristine. J Am Podiatr Med Assoc 93 : 229 233.
132. Osborne WL, Holyoake TL, McQuaker IG, Parker AN (2004). Fatal peripheral neuropathy following FLA chemotherapy. Clin Lab Haematol 26 : 295 296.
133. Ozols RF, Ostchega Y, Myers CE, Young RC (1985). High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 3 : 1246 1250.
134. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B, Cognetti F, Bove L (2003). Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21 : 927 931.
135. Pan YA, Misgeld T, Lichtman JW, Sanes JR (2003). Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J Neurosci 23 : 11479 11488.
136. Parkin DM, Pisani P, Ferlay J (1999). Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 : 827 841.
137. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS (1997). High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol 15 : 2378 2384.
138. Paulson JC, McClure WO (1975). Inhibition of axoplasmic transport by colchicine, podophyllotoxin, and vinblastine: an effect on microtubules. Ann N Y Acad Sci 253 : 517 527.
139. Perez-Ruixo JJ, Chen W, Zhang S, Hayes S, Chow A (2007). Exposure-toxicity relationships for tipifarnib in cancer patients. Br J Clin Pharmacol 64 : 219 232.
140. Pisani P, Parkin DM, Bray F, Ferlay J (1999). Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83 : 18 29.
141. Planting AS, Catimel G, de Mulder PH, de Graeff A, Hoppener F, Verweij J, Oster W, Vermorken JB (1999). Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann Oncol 10 : 693 700.
142. Podratz JL, Schlattau AW, Chen BK, Knight AM, Windebank AJ (2007). Platinum adduct formation in mitochondrial DNA may underlie the phenomenon of coasting. J Peripher Nerv Syst 12 : 69.
143. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ (1995). Paclitaxel-induced neuropathy. Ann Oncol 6 : 489 494.
144. Qweider M, Gilsbach JM, Rohde V (2007). Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine 6 : 280 283.
145. Rago RP, Miles JM, Sufit RL, Spriggs DR, Wilding G (1994). Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans. Cancer 73 : 1954 1959.
146. Ramirez JJ, Kaufmann SH, Windebank AJ (1996). Paclitaxel potentiates cisplatin neurotoxicity in dorsal root ganglion neurons. Neurology 46 : A288.
147. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998). Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9 : 1053 1071.
148. Richardson P, Jagannath S, Colson K (2006a). Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clin Adv Hematol Oncol 4 : 1 discussion 8; suppl 13.
149. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 : 2609 2617.
150. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC (2006b). A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108 : 3458 3464.
151. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006c). Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24 : 3113 3120.
152. Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A (1997). A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 67 : 172 177.
153. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA (2007). Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25 : 1741 1746.
154. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L (1984). Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34 : 934 938.
155. Rose PG (1996). Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Semin Oncol 23 : 83 89.
156. Russell JA, Powles RL (1974). Letter: neuropathy due to cytosine arabinoside. Br Med J 4 : 652 653.
157. Russell JW, Windebank AJ, Podratz JL (1994). Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann Neurol 36 : 221 228.
158. Russell JW, Gill JS, Sorenson EJ, Schultz DA, Windebank AJ (2001). Suramin-induced neuropathy in an animal model. J Neurol Sci 192 : 71 80.
159. Sahenk Z, Brady ST, Mendell JR (1987). Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve 10 : 80 84.
160. Saif MW, Wilson RH, Harold N, Keith B, Dougherty DS, Grem JL (2001). Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and
161. Saif MW, Wood TE, McGee PJ, Diasio RB (2004). Peripheral neuropathy associated with capecitabine. Anticancer Drugs 15 : 767 771.
162. Sanderson PA, Kuwabara T, Cogan DG (1976). Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol 81 : 146 150.
163. Schaumburg H (2000). Vinca Alkaloids. In : Experimental and Clinical Neurotoxicology, 2nd Edn. Schaumburg H, Spencer P (Eds). Oxford University Press, New York. pp 1232 1235.
164. Schmidinger M, Budinsky AC, Wenzel C, Piribauer M, Brix R, Kautzky M, Oder W, Locker GJ, Zielinski CC, Steger GG (2000). Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr 112 : 617 623.
165. Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC (2000). Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82 : 966 972.
166. Scuteri A, Nicolini G, Miloso M, Bossi M, Cavaletti G, Windebank AJ, Tredici G (2006). Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res 26 : 1065 1070.
167. Shibutani M, Okeda R, Hori A, Schipper H (1989). Methotrexate-related multifocal axonopathy. Report of an autopsy case. Acta Neuropathol (Berl) 79 : 333 335.
168. Shingleton BJ, Bienfang DC, Albert DM, Ensminger WD, Chandler WF, Greenberg HS (1982). Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 100 : 1766 1772.
169. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, Tedeschi M (1997). Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 8 : 569 573.
170. Spivack SD (1974). Drugs 5 years later: procarbazine. Ann Intern Med 81 : 795 800.
171. Stein ME, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T (1998). A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am J Clin Oncol 21 : 248 249.
172. Stillman M, Cata JP (2006). Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 10 : 279 287.
173. Sun X, Windebank AJ (1996a). Calcium in suramin-induced rat sensory neuron toxicity in vitro. Brain Res 742 : 149 156.
174. Sun X, Windebank AJ (1996b). Hypoxia potentiates suramin neurotoxicity in rat dorsal root ganglia in vitro. Soc Neurosci Abstr 22 : 948.
175. Ta LE, Espeset L, Podratz J, Windebank AJ (2006). Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27 : 992 1002.
176. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC (1984). Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54 : 1269 1275.
177. van der Hoop RG, Vecht CJ, van der Burg ME, Elderson A, Boogerd W, Heimans JJ, Vries EP, van Houwelingen JC, Jennekens FG, Gispen WH (1990). Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 322 : 89 94.
178. van Gerven JMA, Hovestadt A, Moll JWB, Rodenburg CJ, Splinter TAW, van Oosterom AT, Keizer L, Drogendijk TE, Groenhout CM, Vecht CJ, Neijt JP (1994). The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol 241 : 432 435.
179. van Kooten B, van Diemen HAM, Groenhout KM, Huijgens PC, Ossenkoppele GJ, Nauta JJP, Heimans JJ (1992). A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy. Arch Neurol 49 : 1027 1031.
180. Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ (2005). Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64 : 1076 1077.
181. Voltz RD, Posner JB, Dalmau J, Graus F (1997). Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour. J Neurol Neurosurg Psychiatry 63 : 133 136.
182. Walker M, Ni O (2007). Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol 30 : 82 92.
183. Walsh TJ, Clark AW, Parhad IM, Green WR (1982). Neurotoxic effects of cisplatin therapy. Arch Neurol 39 : 719 720.
184. Weiss S, Kahn Y (1978). Intrathecal methotrexate causing paraplegia in a middle-aged woman. Acta Haematol 60 : 59 61.
185. Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL (2006). A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 24 : 515 520.
186. Wilson WB, Perez GM, Kleinschmidt-Demasters BK (1987). Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation. Cancer 59 : 901 907.
187. Windebank AJ (2005). Metal Neuropathy. In : Peripheral Neuropathy. Dyck PJ, Thomas PK (Eds). Elsevier, Philadelphia. pp 2527 2552.
188. Windebank AJ, McDonald E (2002). Cell death in the peripheral nervous system: potential rescue strategies. Neuroscientist 8 : 62 72.
189. Windebank KA, Podratz JL, Windebank AJ (1996). An in vitro model system for predicting neurotoxicity of new chemotherapeutic agents. Ann Neurol 40 : 491.